↓ Skip to main content

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

Overview of attention for article published in Molecular Cancer, October 2012
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Published in
Molecular Cancer, October 2012
DOI 10.1186/1476-4598-11-75
Pubmed ID
Authors

Sara A Byron, David C Loch, Candice L Wellens, Andreas Wortmann, Jiayi Wu, John Wang, Kenichi Nomoto, Pamela M Pollock

Abstract

Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies. Despite these advances, resistance remains an issue, as illustrated recently by the clinical experience with vemurafenib. Such acquired resistance appears to be the result of parallel pathway activation, such as PI3K, to overcome single-agent inhibition. In this report, we describe the cytotoxicity and anti-tumour activity of the novel MEK inhibitor, E6201, in a broad panel of melanoma cell lines (n = 31) of known mutational profile in vitro and in vivo. We further test the effectiveness of combining E6201 with an inhibitor of PI3K (LY294002) in overcoming resistance in these cell lines.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 3%
Unknown 39 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 25%
Student > Master 9 23%
Researcher 9 23%
Professor > Associate Professor 2 5%
Lecturer 1 3%
Other 4 10%
Unknown 5 13%
Readers by discipline Count As %
Agricultural and Biological Sciences 10 25%
Medicine and Dentistry 10 25%
Biochemistry, Genetics and Molecular Biology 9 23%
Chemistry 2 5%
Physics and Astronomy 1 3%
Other 3 8%
Unknown 5 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2012.
All research outputs
#11,100,715
of 12,483,518 outputs
Outputs from Molecular Cancer
#911
of 1,055 outputs
Outputs of similar age
#109,286
of 128,830 outputs
Outputs of similar age from Molecular Cancer
#2
of 2 outputs
Altmetric has tracked 12,483,518 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,055 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 128,830 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.